GSK) chronic obstructive pulmonary disease (COPD) treatments, Trelegy Ellipta and Breo Ellipta. Under the Inflation Reduction Act, CMS is negotiating prices for select Medicare Part D drugs.
GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...
Singapore’s Health Sciences Authority (HSA) has expanded the label of GlaxoSmithKline (GSK)’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to ...
The higher prices of two COPD inhalers from GSK that are targeted in the second round of government drug price negotiations ...
GSK) chronic obstructive pulmonary disease (COPD) treatments, Trelegy Ellipta and Breo Ellipta. Under the Inflation Reduction Act, CMS is negotiating prices for select Medicare Part D drugs. In the ...
GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback